Efficacy and Safety of Endoscopic Through-the-Scope Suture System for Gastrointestinal Defects

医学 肌切开术 穿孔 外科 荟萃分析 粘膜切除术 梅德林 随机对照试验 内窥镜检查 内科学 贲门失弛缓症 食管 材料科学 政治学 法学 冲孔 冶金
作者
Muhammad Asif Aziz,Hossein Haghbin,Manesh Kumar Gangwani,Azizullah Beran,Dushyant Singh Dahiya,Hassam Ali,Amir Humza Sohail,Wade Lee‐Smith,Syed Uzair Hamdani,Faisal Kamal,Douglas G. Adler
出处
期刊:Journal of Clinical Gastroenterology [Lippincott Williams & Wilkins]
标识
DOI:10.1097/mcg.0000000000002019
摘要

Objective: Recently, a through-the-scope suturing (TTSS) system has received FDA approval and has been evaluated for closing mucosal defects postintervention. We hereby performed a systematic review and pooled meta-analysis of available studies to assess the safety and efficacy of this intervention. Methods: We queried the following databases through April 26, 2023: Embase, MEDLINE, Cochrane Central Register of Controlled Trials, and Web of Science Core Collection. Endoscopists utilizing TTSS for the following reasons were included: endoscopic mucosal resection, endoscopic submucosal dissection, peroral endoscopic myotomy, perforation, fistula closure, and/or stent fixation. The outcomes assessed were technical success, primary clinical success (closure of defect without additional intervention), and overall clinical success (closure of defect with/without additional intervention). Random effects model with the DerSimonian Laird approach was used to report event rates expressed as proportions with a 95% CI. Results: A total of 12 studies with 512 patients (mean age of 61.5 ± 18.4 y, 54.6% females) were included. The technical success rate was 96.0% (CI: 94.3%-97.7%). The primary clinical success rate was 74.8% (CI: 65.5%-84.1%). The overall clinical success rate was 95.4% (CI: 92.6-98.2%). Only 1 mortality case unrelated to intervention was reported. Conclusion: The TTSS appears safe and effective for closing mucosal defects after therapeutic endoscopic interventions. Further cost-effective studies should be performed comparing with endoclips for use in clinical settings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
喵咪西西完成签到 ,获得积分10
1秒前
默然的歌完成签到 ,获得积分10
3秒前
大模型应助科研通管家采纳,获得30
3秒前
huzi完成签到,获得积分10
6秒前
weila完成签到 ,获得积分10
6秒前
成事在人307完成签到,获得积分10
9秒前
胖胖玩啊玩完成签到 ,获得积分10
9秒前
小马甲应助惠飞薇采纳,获得10
9秒前
G哟X完成签到 ,获得积分10
10秒前
basil完成签到,获得积分10
12秒前
Silence完成签到 ,获得积分10
12秒前
开朗惋庭完成签到 ,获得积分10
12秒前
12秒前
成就绮琴完成签到 ,获得积分10
13秒前
fusheng完成签到 ,获得积分0
15秒前
小超完成签到,获得积分10
16秒前
大雪完成签到 ,获得积分10
20秒前
steven完成签到 ,获得积分10
20秒前
量子星尘发布了新的文献求助10
21秒前
叽里呱啦完成签到 ,获得积分10
21秒前
23秒前
陈怼怼完成签到,获得积分10
24秒前
25秒前
LALALALA完成签到,获得积分10
26秒前
jianjiao发布了新的文献求助10
27秒前
幽默的迎天完成签到,获得积分10
29秒前
Loong完成签到,获得积分10
32秒前
1661321476完成签到,获得积分10
37秒前
听寒完成签到,获得积分10
38秒前
量子星尘发布了新的文献求助10
39秒前
冰山一脚尖完成签到,获得积分10
40秒前
徐老师完成签到 ,获得积分10
41秒前
43秒前
安详的灰狼完成签到 ,获得积分10
43秒前
hu完成签到,获得积分10
43秒前
JiangYifan完成签到 ,获得积分10
44秒前
Am1r完成签到 ,获得积分10
44秒前
和谐续完成签到 ,获得积分10
47秒前
浮生完成签到 ,获得积分10
47秒前
bonhiver完成签到 ,获得积分10
48秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Introductory Chemistry 400
Life: The Science of Biology Digital Update 400
Sociologies et cosmopolitisme méthodologique 400
Why America Can't Retrench (And How it Might) 400
Another look at Archaeopteryx as the oldest bird 390
Parenchymal volume and functional recovery after clamped partial nephrectomy: potential discrepancies 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 催化作用 遗传学 冶金 电极 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 4683302
求助须知:如何正确求助?哪些是违规求助? 4058464
关于积分的说明 12546391
捐赠科研通 3754283
什么是DOI,文献DOI怎么找? 2073609
邀请新用户注册赠送积分活动 1102528
科研通“疑难数据库(出版商)”最低求助积分说明 981838